Vivek Bhaskaran

755 total citations
10 papers, 270 citations indexed

About

Vivek Bhaskaran is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Vivek Bhaskaran has authored 10 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Cancer Research and 2 papers in Oncology. Recurrent topics in Vivek Bhaskaran's work include MicroRNA in disease regulation (4 papers), RNA modifications and cancer (3 papers) and Circular RNAs in diseases (2 papers). Vivek Bhaskaran is often cited by papers focused on MicroRNA in disease regulation (4 papers), RNA modifications and cancer (3 papers) and Circular RNAs in diseases (2 papers). Vivek Bhaskaran collaborates with scholars based in United States, Italy and Saudi Arabia. Vivek Bhaskaran's co-authors include E. Antonio Chiocca, Pierpaolo Peruzzi, Carmela Passaro, Sean Lawler, Josie Hayes, Mariano S. Viapiano, Mohan S. Nandhu, Maria C. Speranza, Quazim A. Alayo and John A. McNulty and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Oncogene.

In The Last Decade

Vivek Bhaskaran

9 papers receiving 267 citations

Peers

Vivek Bhaskaran

MB

CR

ONCOL

GENET

IMMUN

Naiara Martínez-Vélez Spain

Davide Ceresa Italy

Noelia Maldonado‐Pérez Spain

Simone Haas Germany

Bauke de Boer Netherlands

Antonella Padella Italy

Joris H. Hageman Netherlands

B. Florien Westendorp Netherlands

Bianca J. Diaz United States

Laura Deedigan Ireland

Naiara Martínez-Vélez Spain

Vivek Bhaskaran

159 ×1.0

MB

53 ×0.6

CR

168 ×1.8

ONCOL

146 ×1.7

GENET

53 ×0.9

IMMUN

Citations per year, relative to Vivek Bhaskaran Vivek Bhaskaran (= 1×) peers Naiara Martínez-Vélez

Countries citing papers authored by Vivek Bhaskaran

Since Specialization

Citations

This map shows the geographic impact of Vivek Bhaskaran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Bhaskaran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Bhaskaran more than expected).

Fields of papers citing papers by Vivek Bhaskaran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek Bhaskaran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Bhaskaran. The network helps show where Vivek Bhaskaran may publish in the future.

Co-authorship network of co-authors of Vivek Bhaskaran

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek Bhaskaran. A scholar is included among the top collaborators of Vivek Bhaskaran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek Bhaskaran. Vivek Bhaskaran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Hyer, Marc L., David A. Gallo, Vivek Bhaskaran, et al.. (2023). Abstract C163: KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition. Molecular Cancer Therapeutics. 22(12_Supplement). C163–C163. 2 indexed citations

2.

Roulston, Anne, Rita de Cássia Stocco, Gianvito Martino, et al.. (2022). The PKMYT1 inhibitor RP-6306 has synergistic efficacy with carboplatin in CCNE1 amplified tumor models. European Journal of Cancer. 174. S61–S61.

3.

Bhaskaran, Vivek, Michal O. Nowicki, Miguel A. Jiménez, et al.. (2019). The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nature Communications. 10(1). 442–442. 88 indexed citations

4.

Bhaskaran, Vivek, Yizheng Yao, Fengfeng Bei, & Pierpaolo Peruzzi. (2019). Engineering, delivery, and biological validation of artificial microRNA clusters for gene therapy applications. Nature Protocols. 14(12). 3538–3553. 14 indexed citations

5.

Bhaskaran, Vivek & Pierpaolo Peruzzi. (2019). Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy. Journal of Visualized Experiments. 2 indexed citations

6.

Peruzzi, Pierpaolo & Vivek Bhaskaran. (2019). MicroRNAs in Brain Cancer: Look at the Forest, Not at the Tree. SHILAP Revista de lepidopterología. 13. 2212839885–2212839885. 1 indexed citations

7.

Passaro, Carmela, Quazim A. Alayo, Isabel DeLaura, et al.. (2018). Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clinical Cancer Research. 25(1). 290–299. 103 indexed citations

8.

Nandhu, Mohan S., Prajna Behera, Vivek Bhaskaran, et al.. (2017). Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma. Clinical Cancer Research. 24(4). 821–833. 28 indexed citations

9.

Nandhu, Mohan S., Aneta Kwiatkowska, Vivek Bhaskaran, et al.. (2017). Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment. Oncogene. 36(34). 4875–4886. 30 indexed citations

10.

Bhaskaran, Vivek, et al.. (2010). Online Surveys For Dummies. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact